These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 28061437)

  • 1. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.
    Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
    Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic modifications but not genetic polymorphisms regulate KEAP1 expression in colorectal cancer.
    Gao L; Yuan F; Che G; Xiao X; Nie X; Wang Y; Jia J; Kong AN; Zhang L
    J Cell Biochem; 2019 Aug; 120(8):12311-12320. PubMed ID: 30825237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic versus Genetic Deregulation of the KEAP1/NRF2 Axis in Solid Tumors: Focus on Methylation and Noncoding RNAs.
    Fabrizio FP; Sparaneo A; Trombetta D; Muscarella LA
    Oxid Med Cell Longev; 2018; 2018():2492063. PubMed ID: 29643973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of Keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression.
    Huang H; Wu Y; Fu W; Wang X; Zhou L; Xu X; Huang F; Wu Y
    Int J Mol Med; 2019 May; 43(5):2044-2054. PubMed ID: 30896860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional and epigenetic characterization of the KRT19 gene in renal cell neoplasms.
    Paiva F; Duarte-Pereira S; Costa VL; Ramalho-Carvalho J; Patrício P; Ribeiro FR; Lobo F; Oliveira J; Jerónimo C; Henrique R
    DNA Cell Biol; 2011 Feb; 30(2):85-90. PubMed ID: 20874491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors.
    Sparaneo A; Fabrizio FP; la Torre A; Graziano P; Di Maio M; Fontana A; Bisceglia M; Rossi A; Pizzolitto S; De Maglio G; Tancredi A; Grimaldi F; Balsamo T; Centra F; Manzorra MC; Trombetta D; Pantalone A; Bonfitto A; Maiello E; Fazio VM; Muscarella LA
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma.
    Chang K; Chen Y; Zhang X; Zhang W; Xu N; Zeng B; Wang Y; Feng T; Dai B; Xu F; Ye D; Wang C
    Cancer Res; 2023 Dec; 83(23):3940-3955. PubMed ID: 37713596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma.
    Liu Q; Jin J; Ying J; Sun M; Cui Y; Zhang L; Xu B; Fan Y; Zhang Q
    Int J Mol Sci; 2015 May; 16(5):10636-49. PubMed ID: 25970749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypermethylation of the Keap1 gene inactivates its function, promotes Nrf2 nuclear accumulation, and is involved in arsenite-induced human keratinocyte transformation.
    Wang D; Ma Y; Yang X; Xu X; Zhao Y; Zhu Z; Wang X; Deng H; Li C; Gao F; Tong J; Yamanaka K; An Y
    Free Radic Biol Med; 2015 Dec; 89():209-19. PubMed ID: 26409248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulation of PAX2 expression in renal cell tumours: mechanisms and potential use in differential diagnosis.
    Patrício P; Ramalho-Carvalho J; Costa-Pinheiro P; Almeida M; Barros-Silva JD; Vieira J; Dias PC; Lobo F; Oliveira J; Teixeira MR; Henrique R; Jeronimo C
    J Cell Mol Med; 2013 Aug; 17(8):1048-58. PubMed ID: 23890189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.
    Du Z; Li L; Huang X; Jin J; Huang S; Zhang Q; Tao Q
    Oncotarget; 2016 Apr; 7(16):21618-30. PubMed ID: 26943038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.
    Breault JE; Shiina H; Igawa M; Ribeiro-Filho LA; Deguchi M; Enokida H; Urakami S; Terashima M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):557-64. PubMed ID: 15701841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer.
    Yamaguchi Y; Kamai T; Higashi S; Murakami S; Arai K; Shirataki H; Yoshida KI
    BMC Cancer; 2019 Nov; 19(1):1137. PubMed ID: 31752777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma.
    Nojima D; Nakajima K; Li LC; Franks J; Ribeiro-Filho L; Ishii N; Dahiya R
    Mol Carcinog; 2001 Sep; 32(1):19-27. PubMed ID: 11568972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
    Namani A; Matiur Rahaman M; Chen M; Tang X
    BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
    Dahl E; Wiesmann F; Woenckhaus M; Stoehr R; Wild PJ; Veeck J; Knüchel R; Klopocki E; Sauter G; Simon R; Wieland WF; Walter B; Denzinger S; Hartmann A; Hammerschmied CG
    Oncogene; 2007 Aug; 26(38):5680-91. PubMed ID: 17353908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MBD1 is an Epigenetic Regulator of KEAP1 in Pancreatic Cancer.
    Zhang B; Xu J; Li C; Shi S; Ji S; Xu W; Liu J; Jin K; Liang D; Liang C; Liu L; Liu C; Qin Y; Yu X
    Curr Mol Med; 2016; 16(4):404-11. PubMed ID: 26980696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma.
    Ooi A; Dykema K; Ansari A; Petillo D; Snider J; Kahnoski R; Anema J; Craig D; Carpten J; Teh BT; Furge KA
    Cancer Res; 2013 Apr; 73(7):2044-51. PubMed ID: 23365135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.
    Zhao Q; Caballero OL; Davis ID; Jonasch E; Tamboli P; Yung WK; Weinstein JN; ; Strausberg RL; Yao J
    Clin Cancer Res; 2013 May; 19(9):2460-72. PubMed ID: 23444225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GULP1 regulates the NRF2-KEAP1 signaling axis in urothelial carcinoma.
    Hayashi M; Guida E; Inokawa Y; Goldberg R; Reis LO; Ooki A; Pilli M; Sadhukhan P; Woo J; Choi W; Izumchenko E; Gonzalez LM; Marchionni L; Zhavoronkov A; Brait M; Bivalacqua T; Baras A; Netto GJ; Koch W; Singh A; Hoque MO
    Sci Signal; 2020 Aug; 13(645):. PubMed ID: 32817372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.